Rating Rationale
January 11, 2021 | Mumbai
Medicamen Biotech Limited
Ratings reaffirmed at 'CRISIL BBB- / Stable / CRISIL A3 '
 
Rating Action
Total Bank Loan Facilities RatedRs.42 Crore
Long Term RatingCRISIL BBB-/Stable (Reaffirmed)
Short Term RatingCRISIL A3 (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its 'CRISIL BBB-/Stable/CRISIL A3' ratings on the bank facilities of Medicamen Biotech Limited (MBL).

 

The ratings continue to reflect MBL’s strong track record in the pharmaceutical industry, and its comfortable financial risk profile. These strengths are partially offset by the modest scale of operations and large working capital requirement.

Key Rating Drivers & Detailed Description

Strengths:

  • Strong track record in the pharmaceutical industry

The nearly two-decade-long presence of the company in the pharmaceuticals industry, and the diversified clientele, comprising the government sector and other customers across India, Africa, and Latin America, will continue to support the business.

 

  • Comfortable financial risk profile

Financial risk profile was marked by a low total outside liabilities to adjusted networth ratio of 0.41 time as on March 31, 2020, (1.52 times as on March 31, 2017). Debt protection metrics were also strong, with interest coverage and net cash accrual to adjusted debt ratios of 21.25 times and 1.16 time, respectively, for fiscal 2020.

 

Weaknesses:

  • Moderate scale of operations

Intense competition may continue to constrain scalability, pricing power and profitability. Revenue was Rs 117.5 crore in fiscal 2020.

 

  • Large working capital requirements

Gross current assets were high at 267 days as on March 31, 2020, driven by the sizeable receivables (139 days) offered to customers. Large credit of 124 days extended by suppliers (active pharmaceutical ingredient manufacturers) partly eases pressure on the working capital cycle.

Liquidity: Adequate

Liquidity should remain adequate. Cash accrual, projected at Rs 14.5 crore and Rs 18.5 crore in fiscals 2021 and 2022, respectively, should comfortably meet the yearly maturing debt of Rs 1.5 crore and Rs 2.7 crore; the surplus cash will be used as working capital. Bank limit utilisation was moderately low, averaging 34% during the 12 months through September 2020. Current ratio was healthy at 1.90 times as on March 31, 2020.

Outlook: Stable

CRISIL Ratings believes MBL will continue to benefit from a strong track record in the pharmaceutical industry.

Rating Sensitivity factors

Upward factors

  • Growth in revenue (by over 20%) and operating margin (by 200 basis points)
  • Substantial and sustained increase in cash accrual
  • Decline in geographic concentration towards African countries

 

Downward factors

  • Fall in revenue by over 10% and steep decline in operating margin
  • Any substantial debt-funded capital expenditure

About the Company

MBL, incorporated in 1993, manufactures pharmaceutical formulations for the overseas and domestic markets. Formulations are based on betalactum, non-betalactum, and cephalosporin drugs. The company is listed on the Bombay Stock Exchange (BSE). In November 2015, Shivalik Rasayan Ltd, another BSE-listed company, along with five persons acting in concert, acquired 44.15% in MBL. MBL has manufacturing facilities in Bhiwadi (Rajasthan) and Haridwar (Uttarakhand).

Key Financial Indicators

Particulars

Unit

2020

2019

Revenue

Rs crore

117.5

122.7

Profit after tax (PAT)

Rs crore

12.26

12.03

PAT margin

%

10.4%

9.8%

Adjusted debt/adjusted networth

Times

0.10

0.14

Adjusted interest coverage

Times

21.24

14.91

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon
rate (%)

Maturity date

Issue size
(Rs cr)

Complexity level

Rating assigned with outlook

NA

Bank Guarantee

NA

NA

NA

1.5

NA

CRISIL A3

NA

Cash Credit

NA

NA

NA

23

NA

CRISIL BBB-/Stable

NA

Letter of Credit

NA

NA

NA

7

NA

CRISIL A3

NA

Proposed Fund-Based Bank Limits

NA

NA

NA

8.82

NA

CRISIL BBB-/Stable

NA

Foreign Exchange Forward

NA

NA

NA

1.68

NA

CRISIL A3

 

Annexure - Rating History for last 3 Years
  Current 2021 (History) 2020  2019  2018  Start of 2018
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities ST/LT 33.5 CRISIL BBB-/Stable / CRISIL A3   --   -- 20-12-19 CRISIL BBB-/Stable 29-09-18 CRISIL BBB-/Stable CRISIL BB+/Stable
Non-Fund Based Facilities ST 8.5 CRISIL A3   --   -- 20-12-19 CRISIL A3 29-09-18 CRISIL A3 CRISIL A4+
All amounts are in Rs.Cr.
 
 
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 1.5 CRISIL A3 Bank Guarantee 3 CRISIL A3
Cash Credit 23 CRISIL BBB-/Stable Cash Credit 18 CRISIL BBB-/Stable
Foreign Exchange Forward 1.68 CRISIL A3 Letter of Credit 10 CRISIL A3
Letter of Credit 7 CRISIL A3 Proposed Fund-Based Bank Limits 11 CRISIL BBB-/Stable
Proposed Fund-Based Bank Limits 8.82 CRISIL BBB-/Stable - - -
Total 42 - Total 42 -
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt

Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
 naireen.ahmed@crisil.com

Nitin Kansal
Director
CRISIL Ratings Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Himank Sharma
Associate Director
CRISIL Ratings Limited
D:+91 124 672 2152
Himank.Sharma@crisil.com


Kishan Gupta
Rating Analyst
CRISIL Ratings Limited
D:+91 124 672 2177
Kishan.Gupta@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 95,000 MSMEs have been rated by us.



CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the “Company) you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit www.crisil.com/privacy. You can view the Company’s Customer Privacy at https://www.spglobal.com/privacy

Last updated: April 2016


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL

CRISIL uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL's use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html